Introduction: Unmet medical needs in rural areas are of grave concern in the U.S. With the advent of digital technologies, the Internet has become a critical means for accessing essential health information. However, racial/ethnic minority rural communities experiencing scarcity in healthcare services and access to the Internet are underrepresented in digital health studies. This study examined the association between online health information-seeking behaviors and unmet medical needs in a sample of African/Black American adults living in a rural region of the U.S.

Methods: Among a sample of 191 adults, we used descriptive analyses to document the level of unmet medical needs and online health information-seeking behaviors of this population and conducted logistic regressions to test the association between online health information-seeking behaviors and unmet medical needs.

Results: Most participants were older than 50 years old (60.2%), female (68.1%), unemployed (57.6%), and had an annual income of less than $25,000 (60.2%). About 20% of participants experienced unmet medical needs. The mean score of online health information-seeking behaviors was 2.37 (range 0-12). Increasing online health information-seeking behaviors was associated with 5.95 increased odds of experiencing unmet medical needs (OR = 5.95, 95% CI 1.27-27.77).

Discussion: The finding highlights that it is necessary to develop targeted programs aimed at populations with high unmet medical needs, focusing on providing accessible health information and resources. Further research is warranted to investigate the motivations to engage in online health information-seeking behaviors to inform structural and workforce interventions to address unmet medical needs in this under-resourced region.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40615-024-02207-6DOI Listing

Publication Analysis

Top Keywords

unmet medical
36
online health
28
health information-seeking
28
information-seeking behaviors
28
health
10
unmet
9
medical
9
association online
8
behaviors unmet
8
online
7

Similar Publications

Background: Osimertinib is the standard first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutated NSCLC. However, treatment resistance is inevitable and increased c-Met protein expression correlates with resistance. Telisotuzumab vedotin (Teliso-V) is an antibody-drug conjugate that targets c-Met protein overexpression.

View Article and Find Full Text PDF

Genetic medicines, including CRISPR/Cas technologies, extend tremendous promise for addressing unmet medical need in inherited retinal disorders and other indications; however, there remain challenges for the development of therapeutics. Herein, we evaluate genome editing by engineered Cas9 ribonucleoproteins (eRNP) in vivo via subretinal administration using mouse and pig animal models. Subretinal administration of adenine base editor and double strand break-inducing Cas9 nuclease eRNPs mediate genome editing in both species.

View Article and Find Full Text PDF

Mechanisms of immunotherapy resistance in small cell lung cancer.

Cancer Drug Resist

December 2024

Department of Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA.

Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a poor prognosis. Although the addition of immunotherapy to chemotherapy has modestly improved outcomes, most patients rapidly develop resistance. Resistance to immunotherapy can be broadly categorized into primary resistance and acquired resistance, as proposed by the Society for Immunotherapy of Cancer (SITC) consensus definition.

View Article and Find Full Text PDF

Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial.

J Hepatol

January 2025

Division of Gastroenterology and Hepatology and Center for Immunology, University of Minnesota, Minneapolis, Minnesota, USA.

Background: Preventing hepatic encephalopathy (HE) recurrence in cirrhosis, which is associated with an altered gut-liver-brain axis, is an unmet need. Fecal microbiota transplantation (FMT) is beneficial in phase-1 studies, but route and dose-related questions remain.

Methods: We performed a phase-2 randomized, placebo-controlled, double-blind, clinical trial of capsule and enema FMT in cirrhosis and HE on lactulose and rifaximin.

View Article and Find Full Text PDF

Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study.

BMC Nephrol

January 2025

Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Key Laboratory of Organ Transplantation, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Huazhong University of Science and Technology, Ministry of Education, Chinese Academy of Medical Sciences, Wuhan, China.

Background: Effective treatment of late antibody-mediated rejection (late AMR) is still an unmet medical need. Clearing donor-specific antibody (DSA) and preventing its rebound is the ideal goal of treatment.

Methods: We have summarized the clinical data from seven patients with late or chronic active AMR after renal transplantation who received daratumumab (Dara)-based treatment first (Phase 1) and then tocilizumab (TCZ) therapy (Phase 2).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!